AllDocs -> cancers

FY02 Ovarian Cancer Research Program Peer Reviewers Bai, Wenlong Ph.D. Baron, Andre T. Ph.D. Biochemistry and Molecular Biology, Mayo Clinic Foundation Batra, Surinder K. Ph.D. Dept. of Biochemistry and Molecular Biology, Univ of Nebraska Medical Ctr., Eppley Cancer Ctr Beck, William T. Ph.D. Department of Biopharmaceutical Sciences, University of Illinois at Chicago Benbrook, Doris M. Ph.D. Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center Bieberich, Charles J. Ph.D. Department of Biological Sciences, University of Maryland Baltimore County Bigbee, William L. Ph.D. Cancer Epidemiology Program, University of Pittsburgh Cancer Institute Blay, Jonathan Ph.D. Dept of Pharmacology, Dalhousie University Faculty of Medicine Bouhassira, Eric E. Ph.D. ...

FERTILITY AND OVARIAN CANCER A study published in January 1993 in the American Journal of Epidemiology (136:1184-1203) suggested a possible association between infertile women using drugs for ovulation induction and ovarian cancer . The study failed to specify, among other important information, the fertility drugs used by affected women. Nevertheless, it generated a lot of media attention and also raised concerns particularly among infertility patients with regard to the safety of the medications commonly prescribed by their physicians. The purpose of this communication is to clarify some of the points in the study that render it severely flawed in its design and conclusions. First, the study based its conclusions on 13 patients with ovarian cancer , 12 who had taken fertility enhancing medications and 1 who had not. The 12 affected patients were the only patients with ovarian cancer who had taken these ...

Rebecca Whelan Oberlin College Development of Assays for Biomarkers of Ovarian Cancer Ovarian cancer presents at an advanced stage in more than 75% of patients, with a five-year survival rate of 30%. If it is diagnosed in stage I, while the cancer is localized to the ovary, the five-year survival rate is 95%. These statistics suggest great potential advantages to be gained from improved early detection of ovarian cancer . A promising area for early detection is the development of assays for serum biomarkers that are expressed in ovarian cancer , even in early-stage disease. Ideally these assays will exhibit high sensitivity, robust performance, ease of use in a clinical setting, and low cost. Current research in our laboratory focuses on two areas: the development of novel antibody-based detection methods for biomarkers of ovarian cancer and the selection and application of single- ...

July, 2002 Ovarian Cancer in Ohio, 1999 This Report Contains: • Ovarian Cancer Incidence by Race, Age and Stage at Diagnosis. • Ovarian Cancer Survival by Stage. • Ovarian Cancer Risk and Protective Factors. The Ohio Cancer Incidence Surveillance System Cancer of the ovary made up 3.5 percent of the incident (newly diagnosed) cancers among females reported to the Ohio Cancer Incidence Surveillance System (OCISS) in 1999 (Table 1). For this period, the age-adjusted ovarian cancer incidence rate was 15.3 cases per 100,000 female Ohio residents, which is 10% lower than the 1999 U.S. rate (from the Surveillance, Epidemiology and End Results Program) of 17.0 per 100,000. In 1999, the age-adjusted mortality rate was 8.6 deaths per 100,000 female Ohio ...

November/December 2001, Vol.8, No.6 Supplement 1 Cancer Control 19 The treatment of advanced ovarian cancer has evolved over the past 20 years. Although effective early diagnosis continues to be elusive and the man- agement of relapsed ovarian cancer does not offer a cure, new therapeutic advances offer many women longer disease-free intervals and improved quality of life with disease. The focus of this program has been to explore the management of advanced ovarian cancer in ways that would promote optimum disease response to various antitumor agents and maximize quality of life during the disease trajectory. For the Nonresponsive or Platinum- Refractory Patient In patients who either do not achieve a clinical response to their initial therapy or who progress while on primary therapy and are considered refrac- tory to platinum,it is clear that standard therapy ...

A PICTURE IS WORTHMUCH NEEDED FUNDS FOR OVARIAN CANCER FOR IMMEDIATE RELEASE TORONTO, ON August 1, 2006 – The National Ovarian Cancer Association is delighted to announce that it is one of the recipients of funds from MillionArtists.com, a website devoted to creating the world’s largest collaborative work of art while raising money for medical charities. Donor-“artists” simply log onto the site and sponsor a coloured pixel which will be added randomly to an abstract painting. Founded by, Eugene Pik and Anthony Barker, the aim is to reach a million people with this initiative. “NOCA is very excited to be a part of this creative initiative! We encourage everyone to raise the flag for ovarian cancer by choosing our colour, a teal pixel and selecting National Ovarian Cancer Association as your charity,” said NOCA Executive Director Elisabeth Ross. Please visit www.MillionArtists.com ...